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Abstract 
 
Indole-3-glycerol phosphate synthase (IGPS) catalyzes the irreversible ring closure of 1-(o-
carboxyphenylamino)-1-deoxyribulose 5- phosphate (CdRP) into indole-3-glycerol phosphate 
(IGP) during the fourth step in tryptophan biosynthesis. Analysis of the crystal structure of IGPS 
from Mycobacterium tuberculosis (MtIGPS) hinted the importance of Lys119 for binding or 
catalysis. Lys110 from sulfolobus sulfataricus IGPS (ssIGPS) that aligns with Lys119 from 
MtIGPS, was proposed to be a general acid for the proton transfer that initiates the ring closure and 
decarboxylation of CdRP. To study the importance of Lys119 in the chemical mechanism for 
MtIGPS, an amino acid change was made at this position to study any changes in catalytic function 
or substrate binding affinity. Kinetic assays were performed and interesting, a mutation to alanine 
had a dramatic effect on the activity of MtIGPS. Our studies highlight the importance of Lys119 in 
the MtIGPS-catalyzed chemical mechanism. 
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Introduction 
 
Mycobacterium tuberculosis (M. tuberculosis), the causative agent for tuberculosis (TB), 
is the top infectious killer in the world13. Despite advances in the development of antimicrobials, 
TB drug development remains quite challenging14. Most of the drugs used to treat TB are very 
old and several have never been studied under stringent conditions. As such, there is an urgent 
need to develop safer, simpler, shorter and more efficacious regimes to treat TB that may be in 
various forms14. TB being among the leading cause of death in several countries, requires 
continuous innovation of drugs to outcompete with antimicrobial drug resistance (AMR)11. 
According to the World Health Organization, multidrug-resistant tuberculosis (MDR-TB) is a 
form of TB that is caused by bacteria with resistance to isoniazid and rifampicin, the 2 strongest, 
primary anti-TB drugs1. As such, research on TB will be essential in developing new anti-TB 
drugs, while combating the future cost of AMR which could cause the global economy to incur 
losses worth US$ 100 trillion by 205012. 
The exploration of indole-3-glycerol phosphate synthase (IGPS) as a potential target for 
TB drug development is of great interest, and has been shown to be essential for the survival of 
M. tuberculosis16. In 1998, Cole and co-worker16 found knockouts in the leucine, proline and 
tryptophan biosynthetic pathways that are unable to replicate in cultured murine macrophages 
and had reduced ability to infect mice, suggesting the lack of these amino acids and their 
importance. They also identified a higher attenuation of virulence especially in the tryptophan 
auxotrophic strain, highlighting the importance of the tryptophan biosynthetic pathway in the 
virulence of M. tuberculosis. Five years later, Sasetti and co-workers used M. tuberculosis 
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transposons to perform in vitro mutagenesis to inactivate the gene that encodes MtIGPS, and 
showed that the IGPS gene is essential for the growth of the pathogen in vitro.21  
Despite the growing interest of using MtIGPS as a potential drug target and for studying 
the virulence of M. tuberculosis, only a few studies on MtIGPS have been reported and one poor 
inhibitor has been identified10. In 2009, Shen and co-workers used homology modeling to deduce 
the structure of IGPS from a virulent strain, M. tuberculosis H37Rv, and screened a library of 
60,000 compounds from the Maybridge database it. They later identified, ATB107 (Figure 1), a 
potential inhibitor that binds tightly to MtIGPS in vitro with a KD of 3 mM and a 50% inhibitory 
concentration of about 0.41 µM. In addition, ATB107 increased the KM value of CdRP 
suggesting it might be a competitive inhibitor for MtIGPS. However, due to the significant 
differences in the structures of CdRP and ATB107, and the low potency, there’s a growing 
interest in developing novel inhibitors that more closely resembles CdRP. This class of inhibitors 
would act as transition state analogues, which are more potent inhibitors. 
 
 
Figure 1. ATB107, a potential inhibitor for MtIGPS that was discovered by Shen and co-
workers10. 
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 IGPS is encoded by the 819 bp trpC gene in the tryptophan operon as a polypeptide 
consisting of 272 amino acids per subunit. IGPS is not found in humans and this fact makes 
IGPS an ideal candidate for anti-tuberculosis treatment. IGPS catalyzes the irreversible ring 
closure of 1- (o-carboxyphenylamino)-1-deoxyribulose 5- phosphate (CdRP) to form indole-3-
glycerol phosphate (IGP), which is accompanied by the release of CO2 and H2O during the 
fourth step of tryptophan biosynthesis (Figure 2). The reaction is irreversible due to the release of 
carbon dioxide and formation of the aromatic indole ring in the second step. The similarity 
between the substrate and product to those in the Bischler-Möhlau indole synthesis, lead Parry20 
to propose that the biotransformation of CdRP to IGP involves the formation of two 
intermediates, 47 years ago. In the proposed mechanism (Figure 2), the first step involves a 
reversible enamine cyclization between the aromatic ring and the carbonyl of CdRP to form the 
first intermediate 3. The next step includes formation of the second intermediate 4 via 
decarboxylation of 3, followed by dehydration of 4 to form the final IGP product. Parry’s 
original suggestion was supported by the crystallography data of IGPS from S. solfataricus IGPS 
(ssIGPS)19 along with electrospray mass spectroscopy studies on IGPS from M. tuberculosis22. 
Czekster and co-workers used ESI(+)-MS to monitor the chemically mimicked intramolecular 
cyclization process of CdRP to IGP. They were able to show the ions attributed to the two 
reaction intermediates and the other major reaction species.    
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Figure 2. The proposed mechanism for the IGPS-catalyzed reaction. The figure was adopted 
from Dr. Nina Goodey and includes some slight modifications. 
IGPS has the typical (β/α)8 barrel, or triosephosphate isomerase (TIM)-barrel fold, which 
consist of eight parallel β -strands in the shape of a barrel that are surrounded by eight α helices. 
IGPS shares the similarity with other TIM-barrel enzymes, in which important amino acid 
residues are located on the β-strands and the loops connecting the β-strands to the α-helices (βα 
loops)25.  Hennig and co-workers19 investigated the enzyme reaction mechanism of ssIGPS 
through X-ray crystallography. Crystal structures of ssIGPS complexed with CdRP and a 
reduced, non-reactive form of CdRP (rCdRP), shows that both CdRP and rCdRP binds to the 
active site in an extended, unproductive confirmation where the two carbon atoms that will 
joined are too far apart (4.5 Å) for bond formation. This suggests that conformational changes in 
the binding pocket are necessary to bring the two carbons closer together4,19. Dr. Goodey and co-
workers2 were able use variants of ssIGPS that were covalently labeled with fluorescent dyes at 
the N-terminal extension of the enzyme and the mobile active site loop, to show that the binding 
and conversion of CdRP to IGP is accompanied by conformational transitions. 
Mutagenesis studies of ssIGPS have identified the importance of several amino acids, 
including Lys110 for the biotransformation4-5. In an earlier proposed mechanism for the ssIGPS-
Overall 
Reaction 
Enamine 
Cyclization 
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catalyzed reaction, Lys110 was predicted to be a general acid in both the ring closure and 
dehydration steps. However, there is no clear mechanism outlining why Lys110 could become 
reprotonated for the second proton transfer (Figure 3B). This inconsistency later lead to an 
alternative hypothesis that suggests that Lys110 only acts as a general acid in the ring closure 
step by donating a proton to the carbonyl of CdRP5 (Figure 3C). 
Kinetic experiments performed by Zaccardi et al. showed that Lys53 (and not Lys110) 
donates the second proton to the C2’ hydroxyl group to catalyze the dehydration of the second 
intermediate (4) to IGP4. Mutations from Lys to Arg and Gln were made at that position to test 
the importance of the positive charge on Lys53 and its ability to act as a general acid. Both 
Lys53 substitutions had substantial effects on the kcat and KM, with K53R having a 10-fold 
decrease in maximum catalytic turnover. The K53Q variant had an almost 700-fold decrease in 
activity even at CdRP concentrations 50 x KM for WT IGPS (12 µM). An alignment of ssIGPS 
and MtIGPS shows that Lys110 corresponds to the Lys119 residue in MtIGPS (Figure 3A).  
 
 
S. Solfataricus  ------MPRYLKGWLKDVVQ----LSLRRPSFRASRQRPIISLNERILEFNKRNITAIIA 50 
M. Tuberculosis  MSPATVLDSILEGVRADVAAREASVSLSEIKAAAAAAPPPLDV----MAALREPGIGVIA 56 
                       :   *:*   **.     :** . .  *:   * :.:    :   :.   .:** 
 
S. Solfataricus  EYKRKSPSGLD--VERDPIEYS-KFMERYAVGLSILTEEKYFNGSYETLRKIASSVSIPI 107 
M. Tuberculosis  EVKRASPSAGALATIADPAKLAQAYQDGGARIVSVVTEQRRFQGSLDDLDAVRASVSIPV 116 
                 * ** ***.    .  ** : :  : :  *  :*::**:: *:** : *  : :*****: 
 
S. Solfataricus  LMKDFIVKESQIDDAYNLGADTVLLIVKILTERELESLLEYARSYGMEPLIEINDENDLD 167 
M. Tuberculosis  LRKDFVVQPYQIHEARAHGADMLLLIVAALEQSVLVSMLDRTESLGMTALVEVHTEQEAD 176 
                 * ***:*:  **.:*   *** :****  * :  * *:*: :.* **  *:*:: *:: * 
 
S. Solfataricus  IALRIGARFIGINSRDLETLEINKENQRKLISMIPSNVVKVAESGISERNEIEELRKLGV 227 
M. Tuberculosis  RALKAGAKVIGVNARDLMTLDVDRDCFARIAPGLPSSVIRIAESGVRGTADLLAYAGAGA 236 
                  **: **:.**:*:*** **:::::   ::   :**.*:::****:    ::      *. 
 
S. Solfataricus  NAFLIGSSLMRNPEKIKEFI---L------------ 248 
M. Tuberculosis  DAVLVGEGLVTSGDPRAAVADLVTAGTHPSCPKPAR 272 
                 :*.*:*..*: . :    .                  
A 
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Figure 3: (A) CLUSTAL O (1.2.4) multiple sequence alignment of the amino acid sequences of 
ssIGPS and MtIGPS showing conserved residues that are suspected to play a role in binding or 
catalysis. The alignment shows that Lys110 from ssIGPS corresponds to Lys119 in MtIGPS. (B) 
The previously propose chemical mechanism for the conversion of CdRP to IGP by IGPS. (C) 
The newly proposed catalytic mechanism for ssIGPS. Figures 3B and 3C were taken from 
Zaccardi et al.4,5 and include slight modifications. 
In this study, we have performed a series of kinetic experiments to elucidate the possible 
role of Lys119 during binding and catalysis for the MtIGPS-catalyzed reaction. Our experiments 
revealed that Lys119 is important for catalysis and could be involved in the binding of CdRP. 
These findings provide a strong insight into the chemical mechanism of MtIGPS.  
CdRP  IGP 
B 
C 
CdRP  IGP 
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2. Materials and Methods 
Materials – All chemicals were of analytical or reagent grade and were used without further 
purification unless otherwise specified.  
2.1 Site-directed Mutagenesis 
2.1.1 Isolation of Plasmid DNA 
MtIGPS exists as a monofunctional enzyme. The trpC coding sequence for MtIGPS cloned in 
pET30a expression vector was purchased from GenScript (New Jersey, USA). The pET30a 
expression vector was isolated from LOBSTR-BL21 (DE3) host cells using slightly modified 
version of Promega’s Wizard® Plus SV Minipreps DNA Purification System. In this updated 
protocol, 5 mL of LB broth (25 g/L) and kanamycin (50 µg/mL) was added to a 15 mL Falcon™ 
conical centrifuge tube, inoculated with host cells previously transformed with the pET30a 
expression vector. The cells were incubated at 37°C for 16-18 hours with shaking at 225 rpm. 
The following day, the bacterial culture was centrifuged 1 mL at a time at 13,000 rpm for 60 
seconds in 1.5 mL microcentrifuge tube, after which the supernatant was discarded. The pelleted 
cells were resuspended in 250 μL of a cell resuspension solution followed by 250 μL of a cell 
lysis solution. The contents were mixed thoroughly by inverting the tube 4–6 times until the 
solution becomes viscous and slightly clear. Alkaline protease solution (10 μL) was added and 
the lysis reaction was timed to ensure that it did not proceed for more than five minutes. A 
neutralization solution (350 μL) was added to the solution and mixed immediately and 
thoroughly by inverting the tube 4–6 times. The mixture was centrifuged for 10 minutes at 
13,000 rpm in a table-top microcentrifuge. The supernatant was removed from the mixture and 
added to a spin column inserted into a collection tube. The spin column was centrifuge for 60 s 
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and the flow-through was discarded. The spin column was washed by adding 0.75 ml of a wash 
solution (ethanol added) and centrifuged for 60 s at 13,000 rpm. The flow-through was discarded 
and the column was centrifuged again at full speed for an additional 60 s to remove residual 
wash solution. The spin column transferred to a clean 1.5 mL microcentrifuge tube and 30 μL of 
nuclease-free water was added to the center of the spin column and allowed to stand for 1 
minute, after which it was centrifuged for 1 minute, to elute the DNA. The DNA was stored at -
80 °C. 
 
2.1.2 Mutant Strand Synthesis 
Site-directed mutagenesis was performed on the MtIGPS gene to achieve the K119A variant for 
this study. Oligonucleotides used in the mutant strand synthesis reactions were supplied by 
Integrated DNA Technologies, Inc (California, USA). The forward primer used to achieve the 
K119A mutation was: 5’-GATTCCGGTTCTGCGCGCGGATTTCGTCGTGCAG-3’ and the 
reverse primer was: 5’-CTGCACGACGAAATCCGCGCGCAGAACCGGAATC-3’. Each 
mutagenesis reaction consist of 0.5 µM of both forward and reverse mutagenic primers, 100 ng 
of DNA template, 0.2 µM dNTPs, and 1X HF buffer (Thermo Fisher Scientific, Cat # F530S) in 
a total volume of 50 µL. One unit of Phusion High‐Fidelity DNA polymerase (Thermo Fisher 
Scientific, Cat # F530S) was added to the reactions, which were performed in a thermal cycler 
(C1000 TouchTM, Thermal cycler, by BIORAD) with appropriate conditions (Table 1). For the 
negative control reaction, primers were excluded from the reaction mix and the other reaction 
components remain unchanged. The final volume of the reaction mix was adjusted to 50 µL 
using nuclease-free water. Following the PCR reactions, 10 units of Dpn I endonuclease (Fisher 
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Scientific, Cat # FERER1701) were added to each reaction and was gently mixed by pipetting the 
solution up and down several times after which it was incubated at 37 °C for an hour. 
 
Table 1. The settings used for various steps in the site-directed mutagenesis reactions. 
 
 
 
 
 
 
 
2.2 Transformation of XL1 Blue and BL21 strains 
The XL1-Blue competent cells were gently thawed on ice. For each control and sample reaction 
to be transformed, 100 µL of cells were added to prechilled 1.5 mL microcentrifuge tubes. Dpn 
I-treated DNA (5 µL) from each reaction was added to separate 1.5 mL microcentrifuge tubes 
containing the XL1-Blue competent cells. The reaction mixtures were gently swirled to mix their 
contents and incubated on ice for 30 minutes. The transformation reactions were placed in a hot 
water bath at 42°C for 45 seconds and the immediately placed on ice for 2 minutes. Sterile LB 
broth (900 µL) was added to each transformation reactions and incubated at 37°C for 1 hour with 
Step Temperature (°C) Time (min.) Cycles 
Initial Denaturation 98 0.5 1X 
1. Denaturation 98 0.5  
             22X 2. Anneal 55 1 
3. Extension 72 3.5 
Final 72 10 1X 
Storage 4 ∞ 1X 
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shaking at 225 rpm. 250 µL of each transformation reaction was placed on preheated agar plates 
supplemented with kanamycin (50 µg/mL), and spread with inoculating loops. The 
transformation plates were incubated 37°C for 18 – 20 hours. The plasmids were isolated from 
two colonies of each transformant as previously described, and sequenced at the Biology 
Department of Montclair State University. 
 
2.3 Expression and Purification  
The expression vectors for both the wild type MtIGPS and the K119A variant were transformed 
in LOBSTR-BL21 (DE3) host cells as previously described for the transformation of XL1-Blue 
competent cells. Starter cultures for each protein to be expressed were grown to saturation for 
16-18 hours at 37 °C with shaking (225 rpm).  The following day, previously autoclaved LB 
media (250 mL) supplemented with kanamycin (50 µg/ml), was inoculated with 1% of the 
saturated overnight culture (v/v). The expression cultures were grown at 37 °C until the 
absorbance (A600) reached a value of 0.5-0.6. IPTG was added to the cell culture to a final 
concentration of 1 mM and the cell culture was incubated for 16-18 hours at 25 °C with shaking 
(225 rpm). The cells were harvested by centrifugation at 5,000 rpm for 15 minutes at 4 °C. The 
recombinant IGPS was purified by Ni-NTA His•Binding resin affinity chromatography with 
buffers at 8.0 pH and 4 °C using a Gravity-flow Column.  The harvested cells were resuspended 
in 15 mL equilibration buffer (1X PBS, 10 mM imidazole) and broken by sonication. The lysate 
was centrifuged at 15,000 rpm, 4 °C for 10 minutes. The supernatant was carefully removed and 
used for purification. The Gravity-flow Column was placed on a stand and packed with 2 mL of 
HisPurTM Ni-NTA resin (Cat # 88222). The storage buffer (buffer in the resin) was allowed to 
drain from resin by gravity flow. The column was equilibrated with three resin-bed volumes of 
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equilibration buffer and the buffer was allowed to drain from column. The equilibration process 
was then repeated for a second time. The protein extract (supernatant from the lysate) was added 
to the resin. The flow-through was collected in a 15 mL Falcon™ conical centrifuge tube. The 
resin was washed with two resin-bed volumes of wash buffer and the flow-through was collected 
in separate 15 mL Falcon™ conical centrifuge tubes. This step was repeated using a new 
collection tube until a Bradford test showed no difference between the colors for the control 
solution and the flow-through being tested. For the Bradford test, 20 µL of Bradford reagent 
(1X) and 80 µL of the flow-through was mixed in a 96 well microtiter plate. The color of the 
flow-through was compared to the control solution (20 µL of 1X Bradford reagent and 80 µL of 
the wash buffer). The enzymes were eluted from the resin with four resin-bed volumes of elution 
buffer and collected in 1 mL fractions in separate microcentrifuge tubes, kept on ice. . This step 
was repeated using a new collection tube until a Bradford test showed no difference between the 
colors for the control solution (20 µL of 1X Bradford reagent and 80 µL of the elution buffer) 
and the flow-through. The purified recombinant IGPS was dialyzed against 5 mM Tris-HCl 
buffer (pH 7.9) and stored at -80 °C. The absorbance of the purified IGPS at 280 nm and its 
molar extinction coefficient (4595 M-1 cm-1) obtained from ExPASy’s ProtParam23 online 
calculator was used to determine its concentration. 
 
2.4 CdRP Concentration Determination 
The chemical synthesis of CdRP was optimized by Dr. David Konas’ lab (Department of 
Chemistry and Biochemistry, Montclair State University, NJ), following a previously reported 
protocol6-7. A solution of anthranilic acid (1.0 mmol) in 700 μL of 1:1 (v:v) iPrOH / EtOH was 
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added a solution of ribose-5-phosphate (0.5 mmol) in 2.0 mL of 2:1 (v:v) iPrOH / H2O. The 
mixture was mixed, stored in the dark at room temperature overnight. The remaining solvents 
were decanted off and the oil was washed with ethyl acetate and diethyl ether. Barium acetate 
was added to precipitate the CdRP product. The solid was collected by centrifugation and 
washed repeatedly with portions of H2O, iPrOH, and EtOAc. With each washing, the solid 
product was collected by centrifugation and the solvent was decanted. The final product was 
dried under vacuum at room temperature and obtained as a light yellow solid. Na2SO4 was added 
to the crude CdRP product to change the CdRP counterion from barium to sodium, which 
increases its solubility in water. The concentration of CdRP was determined by measuring its 
absorbance at 330 nm17 and using its molar extinction coefficient, 0.1415 mM-1 cm-1, which was 
determined from preliminary experiments by weighing.  
 
2.5 Enzymatic Assays  
All assays were performed at 25 °C and measurements were done in triplicates, unless stated 
otherwise. The activity of MtIGPS was determined by measuring the increase of absorbance 
intensity at 280 nm. Data points were collected once every two seconds. The assays were 
performed in 100 mM PIPES, 1 mM DTT, at pH 7.5. The increase in absorbance at 278 nm due 
to the formation of IGP was monitored for 10 minutes using a spectrophotometer (Evolution 201 
UV-visible spectrophotometer, Thermo Scientific) after combining 600 µM CdRP and 3 µM 
MtIGPS in a 1 mL cuvette. A previously reported molar extinction coefficient of 5,500 M-1 cm-1 
was used for IGP9. Control reactions were performed with MtIGPS or CdRP only to determine 
baseline absorbance values attributed to both species. Fluorescence spectroscopy (280 nm 
excitation; 340 nm emission) were performed using a spectrofluorometer (FluoroMAax-4, 
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Horiba Jobin Yvon) with 5 nm and 10 nm slits for the excitation and emission wavelengths 
respectively. Activity assays were performed with 40 nM of MtIGPS and 200 µM of CdRP in 
100 mM PIPES, 1 mM DTT, 5mM EDTA at pH 7.5. The KM values were determined in the 
fluorometer as described above except that the CdRP concentration ranged from 200 µM to 
3.125 µM, and the slits used were 2 times larger for each wavelength. The formation of IGP was 
monitored by measuring the increase in fluorescence emission in the fluorometer. Initial rate data 
were fit to the Michaelis-Menten equation using nonlinear regression with the program 
KaleidaGraph® (version 4.1), using Eqn. 1, where V0 is the initial velocity, kcat is the enzyme’s 
turn-over number, KM is the Michaelis-Menten constant, ET is total enzyme concentration and 
[S] is the substrate concentration. 
 
V0 = (kcat / ET) [S] / (KM + [S])            (Eqn. 1) 
 
3. Results and Discussion 
3.1 Site-directed Mutagenesis 
Sequencing was performed by Adam Parker at Montclair State University with the T7 promoter 
and terminator sequencing primers. The sequencing data were viewed in Chromas (version 
2.6.6.0), which showed the results as DNA sequences. The DNA sequences were translated to 
the amino acid sequences using ExPASy’s online “translate tool”. The amino acid sequence for 
MtIGPS was aligned with the GenScript quote (Figure 4A). A careful analysis of the results 
showed that no mutations were introduced in the MtIGPS protein sequence, which was identical 
to the GenScript quote. The DNA sequence for the sequencing results for K119A was aligned 
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with GenScript quote and a change in the nucleotides that translate to a mutation from lysine to 
alanine was verified (Figure 4B, green). The amino acid sequence for the sequencing results for 
K119A was aligned with the Uniprot MtIGPS (Entry: P9WFX7) and the expected amino acid 
change was identified (Figure 4C, teal). The CLUSTAL O (1.2.4) multiple sequence alignment 
tool from EMBL-EBI was used for the alignments. 
 
Sequencing Results MSPATVLDSILEGVRADVAAREASVSLSEIKAAAAAAPPPLDVMAALREPGIGVIAEVKR 60 
GenScript Quote    MSPATVLDSILEGVRADVAAREASVSLSEIKAAAAAAPPPLDVMAALREPGIGVIAEVKR 60 
                   ************************************************************ 
 
Sequencing Results ASPSAGALATIADPAKLAQAYQDGGARIVSVVTEQRRFQGSLDDLDAVRASVSIPVLRKD 120 
GenScript Quote    ASPSAGALATIADPAKLAQAYQDGGARIVSVVTEQRRFQGSLDDLDAVRASVSIPVLRKD 120 
                   ************************************************************ 
 
Sequencing Results FVVQPYQIHEARAHGADMLLLIVAALEQSVLVSMLDRTESLGMTALVEVHTEQEADRALK 180 
GenScript Quote    FVVQPYQIHEARAHGADMLLLIVAALEQSVLVSMLDRTESLGMTALVEVHTEQEADRALK 180 
                   ************************************************************ 
 
Sequencing Results AGAKVIGVNARDLMTLDVDRDCFARIAPGLPSSVIRIAESGVRGTADLLAYAGAGADAVL 240 
GenScript Quote    AGAKVIGVNARDLMTLDVDRDCFARIAPGLPSSVIRIAESGVRGTADLLAYAGAGADAVL 240 
                   ************************************************************ 
 
Sequencing Results VGEGLVTSGDPRAAVADLVTAGTHPSCPKPAR 272 
GenScript Quote    VGEGLVTSGDPRAAVADLVTAGTHPSCPKPAR 272 
                   ******************************** 
 
 
GenScript Quote     ATGAGTCCGGCGACCGTGCTGGATAGTATTCTGGAAGGTGTTCGTGCTGATGTTGCTGCC 60 
Sequencing Results  ATGAGTCCGGCGACCGTGCTGGATAGTATTCTGGAAGGTGTTCGTGCTGATGTTGCTGCC 60 
                    ************************************************************ 
 
GenScript Quote     CGTGAAGCCTCCGTTTCTCTGTCTGAAATCAAAGCAGCAGCAGCTGCAGCACCGCCGCCG 120 
Sequencing Results  CGTGAAGCCTCCGTTTCTCTGTCTGAAATCAAAGCAGCAGCAGCTGCAGCACCGCCGCCG 120 
                    ************************************************************ 
 
GenScript Quote     CTGGATGTTATGGCAGCTCTGCGTGAACCGGGCATTGGTGTGATCGCAGAAGTTAAACGT 180 
Sequencing Results  CTGGATGTTATGGCAGCTCTGCGTGAACCGGGCATTGGTGTGATCGCAGAAGTTAAACGT 180 
                    ************************************************************ 
 
GenScript Quote     GCAAGTCCGTCCGCAGGTGCTCTGGCAACCATCGCGGACCCGGCAAAGCTGGCCCAGGCA 240 
Sequencing Results  GCAAGTCCGTCCGCAGGTGCTCTGGCAACCATCGCGGACCCGGCAAAGCTGGCCCAGGCA 240 
                    ************************************************************ 
 
GenScript Quote     TATCAAGATGGCGGTGCGCGTATTGTGAGTGTGGTGACGGAACAGCGTCGCTTTCAAGGT 300 
Sequencing Results  TATCAAGATGGCGGTGCGCGTATTGTGAGTGTGGTGACGGAACAGCGTCGCTTTCAAGGT 300 
A 
B 
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                    ************************************************************ 
 
GenScript Quote     TCCCTGGATGACCTGGACGCAGTCCGTGCTTCAGTGTCGATTCCGGTTCTGCGCAAGGAT 360 
Sequencing Results  TCCCTGGATGACCTGGACGCAGTCCGTGCTTCAGTGTCGATTCCGGTTCTGCGCGCGGAT 360 
                    ******************************************************  **** 
 
GenScript Quote     TTCGTCGTGCAGCCGTACCAAATCCATGAAGCTCGTGCACACGGTGCAGACATGCTGCTG 420 
Sequencing Results  TTCGTCGTGCAGCCGTACCAAATCCATGAAGCTCGTGCACACGGTGCAGACATGCTGCTG 420 
                    ************************************************************ 
 
GenScript Quote     CTGATTGTTGCGGCCCTGGAACAGAGCGTTCT-GGTCTCTATGCTGGATCGCACCGAAAG 479 
Sequencing Results  CTGATTGTTGCGGCCCTGGAACAGAGCGTTCTGGGTCTCTATGCTGGATCGCACCGAAAG 480 
                    ******************************** *************************** 
 
GenScript Quote     CCTGGGTATGACGGCGCTGGTTGAAGTTCATACCGAACAGGAAGCGGACCGTGCACTGAA 539 
Sequencing Results  CCTGGGTATGACGGCGCTGGTTGAAGTTCATACCGAACAGGAAGCGGACCGTGCACTGAA 540 
                    ************************************************************ 
 
GenScript Quote     AGCAGGTGCAAAGGTTATCGGTGTCAACGCCCGCGATCTGATGACGCTGGATGTTGACCG 599 
Sequencing Results  AGCAGGTGCAAAGGTTATCGGTGTCAACGCCCGCGATCTGATGACGCTGGATGTTGACCG 600 
                    ************************************************************ 
 
GenScript Quote     TGATTGCTTTGCACGCATTGCTCCGGGCCTGCCGAGCTCTGTCATTCGTATCGCAGAAAG 659 
Sequencing Results  TGATTGCTTTGCACGCATTGCTCCGGGCCTGCCGAGCTCTGTCATTCGTATCGCAGAAAG 660 
                    ************************************************************ 
 
GenScript Quote     CGGTGTGCGTGGTACCGCAGACCTGCTGGCTTATGCAGGTGCAGGTGCAGATGCTGTCCT 719 
Sequencing Results  CGGTGTGCGTGGTACCGCAGACCTGCTGGCTTATGCAGGTGCAGGTGCAGATGCTGTCCT 720 
                    ************************************************************ 
 
GenScript Quote     GGTGGGCGAAGGTCTGGTGACGTCTGGTGATCCGCGCGCGGCAGTGGCTGACCTGGTGAC 779 
Sequencing Results  GGTGGGCGAAGGTCTGGTGACGTCTGGTGATCCGCGCGCGGCAGTGGCTGACCTGGTGAC 780 
                    ************************************************************ 
 
GenScript Quote     GGCGGGCACGCATCCGAGTTGTCCGAAACCGGCACGCTAA 819 
Sequencing Results  GGCGGGCACGCATCCGAGTTGTCCGAAACCGGCACGCTAA 820 
                    **************************************** 
 
 
Sequencing Results MSPATVLDSILEGVRADVAAREASVSLSEIKAAAAAAPPPLDVMAALREPGIGVIAEVKR 60 
Uniprot MtIGPS     MSPATVLDSILEGVRADVAAREASVSLSEIKAAAAAAPPPLDVMAALREPGIGVIAEVKR 60 
                   ************************************************************ 
 
Sequencing Results ASPSAGALATIADPAKLAQAYQDGGARIVSVVTEQRRFQGSLDDLDAVRASVSIPVLRKD 120 
Uniprot MtIGPS     ASPSAGALATIADPAKLAQAYQDGGARIVSVVTEQRRFQGSLDDLDAVRASVSIPVLRAD 120 
                   ********************************************************** * 
 
Sequencing Results FVVQPYQIHEARAHGADMLLLIVAALEQSVLVSMLDRTESLGMTALVEVHTEQEADRALK 180 
Uniprot MtIGPS     FVVQPYQIHEARAHGADMLLLIVAALEQSVLVSMLDRTESLGMTALVEVHTEQEADRALK 180 
                   ************************************************************   
 
Sequencing Results AGAKVIGVNARDLMTLDVDRDCFARIAPGLPSSVIRIAESGVRGTADLLAYAGAGADAVL 240 
Uniprot MtIGPS     AGAKVIGVNARDLMTLDVDRDCFARIAPGLPSSVIRIAESGVRGTADLLAYAGAGADAVL 240 
                   ************************************************************  
                                                            
Sequencing Results VGEGLVTSGDPRAAVADLVTAGTHPSCPKPAR 272 
Uniprot MtIGPS     VGEGLVTSGDPRAAVADLVTAGTHPSCPKPAR 272 
          ******************************** 
 
C 
16  
Figure 4: (A) The amino acid sequence alignment results for the sequencing results for MtIGPS 
and the GenScript quote. (B) The alignment of the sequencing results for K119A and the 
GenScript quote DNA sequences. The nucleotide changes that lead to the K119A variant is 
highlighted in green. (C) The amino acid sequence alignment results for the sequencing results 
for K119A and the Uniprot MtIGPS (Entry: P9WFX7). The amino acid change was highlighted 
in teal. The CLUSTAL O (1.2.4) multiple sequence alignment tool from EMBL-EBI was used 
for the alignments. 
 
3.2 Expression and Purification 
MtIGPS and the K119A mutant was expressed in the LOBSTR-BL21 (DE3) strain and purified 
homogenously to a yield of 18.36 ± 0.03 mg and 48.16 ± 0.08 respectively from a 2 g cell pellet, 
obtained from 500 mL LB broth (25 g/L). SDS-PAGE was used to approximate the molecular 
weights of the purified MtIGPS and the K119A mutant (Figure 5), which was similar to the 
predicted molecular weight for the MtIGPS with the His tag (33.5 kDa), that was determined 
using ExPASy’s ProtParam23 online tool (Table 2). The result shows that MtIGPS and the 
K119A mutant were monomers in the solution as previously described18. 
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Figure 5. SDS-PAGE results of the purification of wild type IGPS.  Lane 1, SeeBlue™ Plus2 
Pre-stained Protein Standard (Cat # LC5925); lane 2, elution fraction at the expected molecular 
weight of 33.5 kDa + His tag. 
 
Table 2. Various physical and chemical parameters determined using ExPASy’s ProtParam23 
online tool. 
 
 
 
 
 
 
 
Number of Amino Acids 322 
Molecular Weight 33455.03 Da 
Theoretical pI 5.35 
Extinction Coefficient 4595 M-1 cm-1 
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3.3 Enzymatic Assays  
The biotransformation of CdRP to IGP product was followed by UV-VIS (Figure 6) in a 
spectrophotometer (Cary 100, version12.00). In a 1 mL cuvette, 3 µM of MtIGPS and 600 µM 
CdRP were mixed in 100 mM PIPES and 1 mM DTT at pH 7.5. The experiment was repeated 
for the K119A variant using 3 µM K119A and identical conditions used for the MtIGPS kcat 
determination. Over the course of the reaction, a steady increase in absorbance owing to the 
formation of IGP9 was observed (Figure 6A, triangles). On the other hand, no increase in 
absorbance was detected for the reaction catalyzed by K119A (Figure 6B, squares). A small 
increase in absorbance was also observed for the control reactions. This increase in absorbance 
could be due to the decomposition of CdRP by hydrolysis. The kcat for MtIGPS was determined 
by converting the slope of the reaction (Figure 6A, triangles) to the maximum velocity (M s-1) 
using a previously reported molar extinction coefficient for IGP (5,500 M-1 cm-1)9, and the total 
enzyme concentration in the reaction (3 µM). The kcat value for MtIGPS was found to be 0.021 ± 
0.003 s-1, which is approximately 10 times lower than the value previously determined (0.16 ± 
0.01 s -1 )8. The discrepancy between the kcat values could be attributed to the purity of the CdRP 
used in the assays; the CdRP could have been contaminated with enzyme inhibitors, which could 
be the unreacted substrates from the chemical synthesis or the products from the hydrolysis of 
CdRP. The upper limit for the kcat value for K119A was determined as previously described for 
MtIGPS and was found to be 0.00121 s -1, which is less than 17 fold lower than kcat value for 
MtIGPS (Table 3). 
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Table 3. Steady-state kinetic parameters for MtIGPS and K119A (at pH 7.5). The kcat values 
were determined using saturating concentration of CdRP (600 µM). 3 µM of MtIGPS and 600 
µM CdRP was mixed in 100 mM PIPES and 1 mM DTT at pH 7.5. The kcat was determined by 
converting the slope of the reaction (Figure 5A, triangles) to M s-1 using a previously reported 
molar extinction coefficient for IGP (5,500 M-1 cm-1)9, and the total enzyme concentration in the 
reaction. The kcat for K119A was calculated as described for MtIGPS. The reported errors are 
standard deviations of three trials for each reaction. 
 
 kcat (s-1) 
MtIGPS 0.021 ± 0.003 
K119A < 0.00121 
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Figure 6: (A) Absorbance versus time in seconds for the conversion of CdRP to IGP catalyzed 
by MtIGPS over the period of 600 seconds of a solution of 3 µM MtIGPS and 600 µM CdRP 
(triangles), and 600 µM CdRP only (circles). Both reactions proceeded in 100 mM PIPES and 1 
mM DTT at pH 7.5. (B) Reactions for 3 µM K119A and 600 µM CdRP (squares), and 600 µM 
CdRP only (diamonds). The absorbance data used for the plots was an average of three trials 
performed under identical conditions. No increase in absorbance was observed for the K119A 
reactions relative to the CdRP only control. 
The KM value determined from the initial velocity data was found to be 14 ± 3 µM, 
which is an average of three trials and the error is the standard deviation of the three trials. The 
KM value is more than 3 times lower than the value previously obtained by Czekster et al. (55 ± 
9 µM,)8 and 60 times lower than the value previously obtained by Shen et al. (1.13 mM)10. The 
significant difference in the KM values could be due to the difference in purity of the CdRP 
chemically synthesized. The catalytic efficiency, kcat/KM, for the Mt IGPS is 1.5 x 103 M-1 s-1, 
which is more than two times smaller than previously obtained by Czekster and co-workers (2.9 
x 103 M-1 s-1)8. 
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Figure 7. Representative graph of velocity (ΔCPS/Δseconds) versus CdRP concentrations for a 
trial is shown. Reactions were performed with 40 nM of MtIGPS and various concentration of 
CdRP ranging from 200 µM to 3.125 µM in 100 mM PIPES, 1 mM DTT, 5mM EDTA at pH 
7.5. The slits used were 10 nm and 15 nm for the excitation and emission wavelengths 
respectively. The slopes (ΔCPS/Δseconds) and respective CdRP concentrations from each 
reaction was fitted to the Michaelis-Menten equation (Eqn. 1) to determine the KM value for 
MtIGPS. The fit for MtIGPS-catalyzed reaction was done using the program KaleidaGraph® 
version 4.1. The reactions were performed in triplicate and the average of the three KM values 
was 14 ± 3 µM.  
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The fluorescence emission (280 nm excitation, 5 nm slit; 340 nm emission, 10 nm slit)   
attributed to the formation of IGP was measured for 600 seconds for a solution of 40 nM 
MtIGPS and 200 µM CdRP (Figure 8A, circles), and 200 µM CdRP only (Figure 8B, triangles). 
Both reactions proceeded in 100 mM PIPES, 1 mM DTT, and 5 mM EDTA at pH 7.5. For the 
MtIGPS-catalyzed reaction, a steady increase in fluorescence was observed, which indicated the 
increase in IGP product formation. For the CdRP only control reaction (Figure 8B, triangles), 
there was little to no change in fluorescence, which was expected because there was no enzyme 
present in the reaction. The slight increase in fluorescence could be attributed to the 
decomposition of CdRP. The activity of K119A during the conversion of CdRP to IGP was quite 
difficult to investigate using UV-VIS and fluorescence spectroscopy; we were unable to measure 
the KM and the kcat values for K119A. With increasing amounts of K119A in the assay, there 
was no increase in the fluorescence emission over the course of 10 minutes. However, the initial 
fluorescence emission increases with the enzyme concentration and remains steady over the 
course of the reaction (Figure 8C). Interestingly, UV-VIS spectroscopy data showed an increase 
in absorbance over a period of 10 minutes for a solution of 3 µM MtIGPS and 600 µM CdRP 
(Figure 6A, triangle), suggesting that the reaction was less likely to be completed prior to data 
collection. The increase in initial fluorescence emission with increasing enzyme concentration 
could be due to the increase in emission from tyrosine and possibly phenylalanine in MtIGPS26. 
MtIGPS lacks tryptophan but has four phenylalanine and three tyrosine residues. Teale and 
Weber26 found that tyrosine have two-thirds of the tryptophan fluorescence and tyrosine shows 
strong excitation at 280 nm and emission at 340 nm. On the other hand, phenylalanine has weak 
excitation and emission at 280 and 340 nm respectively, and is expected to have a minor effect 
on the fluorescence emission being recorded by the instrument. 
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Figure 8: (A) Fluorescence emission (280 nm excitation, 5 nm slit ; 340 nm emission, 10 nm 
slit) versus time in seconds for the conversion of CdRP to IGP catalyzed by MtIGPS over the 
period of 600 seconds of a solution of 40 nM MtIGPS and 200 µM CdRP (circles), and 200 µM 
CdRP only(triangles). Both reactions occurred in 100 mM PIPES, 1 mM DTT, and 5 mM EDTA 
at pH 7.5. (B) Reactions catalyzed by K119A after the incubation of: 2 µM K119A and 200 µM 
CdRP (diamonds), 1 µM K119A and 200 µM CdRP (dashed lines), 40 nM MtIGPS + 200 µM 
CdRP (open circles), and 200 µM only (crosses). Little to no increase in fluorescence emission 
was observed for K119A reactions relative to the CdRP only control. (C) Control reactions for: 2 
µM K119A (open diamonds), 1 µM K119A (open squares), 40 nM MtIGPS + 200 µM CdRP 
(open circles), and 200 µM only (crosses). 
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The results of the enzymatic assays show that the Lys119 residue in MtIGPS may be 
important for catalysis. No increase in fluorescence emission or absorbance due to the formation 
of IGP was detectable despite significant increases in the enzyme concentration, which made the 
kcat and KM determination quite challenging. These findings suggest that Lys119 could be 
important for catalysis and is consistent with the ssIGPS proposed mechanism5. Lys119 lies in 
close proximity to the product IGP which suggests that it could be involved in binding or 
catalysis (Figure 9A). An overlay of the crystal structures for ssIGPS and MtIGPS shows the 
similarity between the residues in the binding pocket, which could have similar functions in both 
strains of IGPS (Figure 9B). 
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Figure 9: (A) Crystal structure of MtIGPS in complex with IGP and anthranilate (PDB# 3T44) 
showing interactions between IGP and MtIGPS residues. Lys119 (blue) is 3.54Å from IGP 
(pink).  (B) Structural alignment of ssIGPS (blue; PDB# 1A53) and MtIGPS (brown; PDB# 
3T44). The amino acid residues are numbered according to MtIGPS; Lys119 (red) and Lys110 
(orange; ssIGPS) are shown in close proximity to the IGP product (dark grey). Despite only 
sharing 29% amino acid identity, ssIGPS and MtIGPS show strong structural similarity. 
The results from the enzymatic assay is consistent with the catalytic mechanism for 
ssIGPS (Figure 3B) proposed by Zaccardi et al. in 20134. According to the proposed mechanism, 
a mutation to alanine is expected to prevent the protonation of the carbonyl of CdRP, preventing 
IGP formation4-5. In addition, the analysis of the crystal structure of MtIGPS complexed with 
IGP (Figure 9A) shows Lys119 in close proximity to the product IGP (3.54Å), in a position close 
enough to possibly form a π-cation interaction with the indole ring and may play a role in the 
mechanism. Recently, Dr. Nina Goodey suggested that there are two binding surfaces in IGPS, 
one for CdRP and another for IGP. Based on this information, the mutation from lysine to 
B 
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alanine could have affected the substrate or product binding, and the structural rearrangements 
during catalysis. This would make it quite difficult for MtIGPS to convert CdRP to IGP which is 
reflected in the upper limit for the kcat for K119A, which was at least 17 fold lower than the kcat 
value for MtIGPS (Table 3). In future studies, an unreactive substrate analogue, rCdRP will used 
to investigate the importance of Lys119 during ligand binding as described2. The reduced CdRP 
can be synthesized by selective reduction of CdRP with NaBH427. MtIGPS lacks tryptophan but 
binding parameters may be determined using intrinsic tyrosine fluorescence owing to the fact 
that its quantum yield is high enough to give a good fluorescence signal26. During binding 
events, changes in protein folding can be studied because their quantum yield is sensitive to its 
environment which changes when protein folds/unfolds. 
To elucidate the importance of the positive charge on Lys110 and its ability to act as a 
catalytic acid, mutations to Arg and Gln at that position can be made; Arg retains the positive 
charge and has the ability to donate a proton, whereas Gln lacks both properties but is able to 
participate in CdRP binding via hydrogen bonding with the carboxylate moiety. As a result, a 
mutation to arginine would be expected to have no effect on the enzyme-catalyzed reaction and 
kcat value is expected to be similar to the value for MtIGPS. On the other hand, if no change in 
activity is found (represented by the kcat value), this might indicate that the position may be 
important for binding or orientation of the substrate and/or product. If the mutation to Gln results 
in a decrease in the kcat value, this might suggest that a positive charge and/or the ability for Lys-
119 to act as a general acid are critical for MtIGPS chemical mechanism. However, no effect on 
the kcat would suggest that neither property is important for catalysis. 
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In summary, we characterized Lys119 that is suspected of forming important interactions 
with CdRP to further understand the interactions between IGPS and its ligands. We found that a 
mutation to alanine at that position had a significant effect on the MtIGPS-catalyzed reaction. 
The upper limit for the kcat for K119A was found to be 0.00121 s -1, and is less than 17 fold 
lower than kcat value for MtIGPS (0.021 ± 0.003 s-1). This finding suggests that Lys119 is 
important for catalysis and is consistent with the previously proposed mechanisms (Figure 3B 
and 3C). In addition, the results shows the importance of the carboxylate moiety on C2’ of 
CdRP, which provides an increased understanding of binding interactions and structure-function 
relationships in IGPS and are expected to contribute to the understanding of the mechanism of 
MtIGPS. 
 
 
 
 
 
 
 
 
 
 
30  
References 
1. Yang, Y., Zhang, M., Zhang, H., Lei, J., Jin, R., Xu, S., ... & Wang, H. (2006). 
Purification and characterization of Mycobacterium tuberculosis indole-3-glycerol 
phosphate synthase. Biochemistry (Moscow), 71(1), S38-S43. 
2. Schlee, S., Dietrich, S., Kurćon, T., Delaney, P., Goodey, N. M., & Sterner, R. (2012). 
Kinetic mechanism of indole-3-glycerol phosphate synthase. Biochemistry, 52(1), 132-
142. 
3. Ramaswamy, S. and Musser, J.M., 1998. Molecular genetic basis of antimicrobial agent 
resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and Lung disease, 
79(1), 3-29. 
4. Ramaswamy, S., & Musser, J. M. (1998). Molecular genetic basis of antimicrobial agent 
resistance in Mycobacterium tuberculosis: 1998 update. Tubercle and Lung 
disease, 79(1), 3-29. 
5. Zaccardi, M. J., O'Rourke, K. F., Yezdimer, E. M., Loggia, L. J., Woldt, S., & Boehr, D. 
D. (2014). Loop‐loop interactions govern multiple steps in indole‐3‐glycerol phosphate 
synthase catalysis. Protein Science, 23(3), 302-311. 
6. Smith, D. A., Parish, T., Stoker, N. G., & Bancroft, G. J. (2001). Characterization of 
Auxotrophic Mutants of Mycobacterium tuberculosis and Their Potential as Vaccine 
Candidates. Infection and immunity, 69(2), 1142-1150. 
7. Doy, C. H. (1966). Chemical Synthesis of the Tryptophan Path Intermediate l-(o-
Carboxyphenylamino)-l-deoxy-D-ribulose 5-Phosphate. Nature, 211(5050), 736. 
31  
8. Czekster, C. M., Neto, B. A., Lapis, A. A., Dupont, J., Santos, D. S., & Basso, L. A. 
(2009). Steady-state kinetics of indole-3-glycerol phosphate synthase from 
Mycobacterium tuberculosis. Archives of biochemistry and biophysics, 486(1), 19-26. 
9. Kirschner, K., Szadkowski, H., Jardetzky, T. S., & Hager, V. (1987). [48] 
Phosphoribosylanthranilate isomerase—indoleglycerol-phosphate synthase from 
Escherichia coli. In Methods in enzymology (Vol. 142, pp. 386-397). Academic Press. 
10. Shen, H., Wang, F., Zhang, Y., Huang, Q., Xu, S., Hu, H., ... & Wang, H. (2009). A 
novel inhibitor of indole‐3‐glycerol phosphate synthase with activity against multidrug‐
resistant Mycobacterium tuberculosis. The FEBS journal, 276(1), 144-154. 
11. Gomez, G. B., Dowdy, D. W., Bastos, M. L., Zwerling, A., Sweeney, S., Foster, N., ... & 
Knight, G. M. (2016). Cost and cost-effectiveness of tuberculosis treatment shortening: a 
model-based analysis. BMC infectious diseases, 16(1), 726. 
12. Henn-Sax, M., Höcker, B., Wilmanns, M., & Sterner, R. (2001). Divergent Evolution of 
(β/α) 8-Barrel Enzymes. Biological chemistry, 382(9), 1315-1320.  
13. “Fight to End Tuberculosis | General Assembly of the United Nations.” United Nations, 
United Nations, 26 Sept. 2018, www.un.org/pga/73/event/fight-to-end-tuberculosis/.  
14. Stop, T. B. (2015). Partnership: The Paradigm Shift. 2016-2020. Global Plan to End TB. 
United Nations Office for Project Services, UNOPS, Geneva Switzerland.  
15. “Tuberculosis (TB).” World Health Organization, World Health Organization, 
www.who.int/news-room/fact-sheets/detail/tuberculosis.  
16. Cole, S., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., ... & Tekaia, F. 
(1998). Deciphering the biology of Mycobacterium tuberculosis from the complete 
genome sequence. Nature, 393(6685), 537.  
32  
17. Creighton, T.E. and Yanofsky, C., 1966. Indole-3-glycerol phosphate synthetase of 
Escherichia coli, an enzyme of the tryptophan operon. Journal of Biological Chemistry, 
241(20), 4616-4624.  
18. Smith, O.H. and Yanofsky, C., 1962. [107] Enzymes involved in the biosynthesis of 
tryptophan. In Methods in enzymology (Vol. 5, pp. 794-806). Academic Press.  
19. Hennig, M., Darimont, B.D., Jansonius, J.N. and Kirschner, K., 2002. The catalytic 
mechanism of indole-3-glycerol phosphate synthase: crystal structures of complexes of 
the enzyme from Sulfolobus solfataricus with substrate analogue, substrate, and product. 
Journal of molecular biology, 319(3), 757-766.  
20. Parry, R.J., 1971. Biosynthesis of compounds containing an indole nucleus. Chemistry of 
Heterocyclic Compounds: Indoles, Part Two, 25, 1-64.  
21. Sassetti, C. M., Boyd, D. H., & Rubin, E. J. (2003). Genes required for mycobacterial 
growth defined by high density mutagenesis. Molecular microbiology, 48(1), 77-84. 
22. Czekster, C. M., Lapis, A. A., Souza, G. H., Eberlin, M. N., Basso, L. A., Santos, D. S., 
& Neto, B. A. (2008). The catalytic mechanism of indole-3-glycerol phosphate synthase 
(IGPS) investigated by electrospray ionization (tandem) mass spectrometry. Tetrahedron 
Letters, 49(41), 5914-5917. 
23. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch 
A.; Protein Identification and Analysis Tools on the ExPASy Server; (In) John M. 
Walker (ed): The Proteomics Protocols Handbook, Humana Press (2005). pp. 571-607 
24. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. 
C., & Ferrin, T. E. (2004). UCSF Chimera—a visualization system for exploratory 
research and analysis. Journal of computational chemistry, 25(13), 1605-1612. 
33  
25. O’Rourke, K., Jelowicki, A., & Boehr, D. (2016). Controlling active site loop dynamics 
in the (β/α) 8 barrel enzyme indole-3-glycerol phosphate synthase.Catalysts,6(9), 129. 
26. Teale, F. W. J., & Weber, G. (1957). Ultraviolet fluorescence of the aromatic amino 
acids. Biochemical Journal, 65(3), 476. 
27. Bisswanger, H., Kirschner, K., Cohn, W., Hager, V., & Hansson, E. (1979). N-(5-
Phosphoribosyl) anthranilate isomerase-indoleglycerol-phosphate synthase. 1. A substrate 
analog binds to two different binding sites on the bifunctional enzyme from Escherichia 
coli. Biochemistry,18(26), 5946-5953. 
